Pay in 4 interest-free payments of $5.60 Learn more
Ships within 48 hours · Estimated delivery Aug 28 - Sep 2
Three patients (27%) developed low complement and/or anti-dsDNA antibodies at 6-10 months
By end use, the homecare/direct-to-patient segment is anticipated to show fastest growth during the predicted timeframe
health care system has evolved in a way that's unfair to American patients and taxpayers who disproportionately pay a higher share of the costs for developing breakthrough medicines compared to other countries," Ricks added
This past year, as this therapy class has continued to evolve, as the company worked with the manufacturers to secure a more affordable cost with positive results that allow us the flexibility to continue offering our customers more choice and access for their members
"Evidence in the UK Biobank for the underdiagnosis of erythropoietic protoporphyria"
US$ 22.54
US$ 26.25
US$ 27.48
